Immunotherapy · 2017 · 15 citations · 13 references
Life SciencesHematologyImmunologyCell TherapyImmunotherapyStem Cell TransplantationCancer ImmunotherapyCell-based ImmunotherapyChimeric Antigen Receptor T-cell TherapyDonor Lymphocyte InfusionGraft-versus-host DiseaseTransplant ImmunotherapyAllogeneic Car T-cell TherapyHematologic Malignancy Car T-cell TherapyHematopoietic Stem Cell Transplantation ImmunotherapyImmune Reconstitution After Stem Cell TransplantationLong-term ImmunosuppressionLymphoma RelapseT Cell-based ImmunotherapyTherapeutic Donor Lymphocyte Infusion
Treatment of patients with relapsed or refractory lymphoma may require allogenic hematopoietic stem cell transplant (HSCT), but treatment of post-transplant relapse disease remains very challenging. Donor lymphocyte infusion and blinatumomab have been used with limited success for the treatment of relapse. Initial data on donor-derived CAR T cells has shown this modality to be safe and highly effective in various hematological malignancies. We present a case of a patient with highly refractory, transformed follicular lymphoma who failed both autologous and allogenic HSCT. Patient achieved long-lasting complete remission with the use of donor origin CD19 CAR T-cell therapy, without any evidence of graft-versus-host disease flare. Our patient later developed disseminated coccidioidomycosis and persistent hypogammaglobulinemia. Immunotherapy using CD19 CAR T cells can be a highly effective salvage modality, especially in cases of focal lymphoma relapse. Long-term immunosuppression secondary to B cell lymphopenia, hypogammaglobulinemia, immunoglobulin subclass deficiency, fungal infections and other infectious complications need to be monitored and promptly treated as indicated.
13
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations
Medicine, Hematology, Oncology +15